DMD Digital Health Connections Group Inc Total Liabilities
DMD Digital Health Connections Group Inc total liabilities. Based on the latest financial reports, DMD Digital Health Connections Group Inc (APTOF) has total liabilities worth $37.18 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check DMD Digital Health Connections Group Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of DMD Digital Health Connections Group Inc (2013–2025)
Total liabilities of DMD Digital Health Connections Group Inc from 2013 to 2025. This chart illustrates how DMD Digital Health Connections Group Inc's total liabilities have evolved over time, based on quarterly financial data.
DMD Digital Health Connections Group Inc Competitors by Total Liabilities
The table below lists competitors of DMD Digital Health Connections Group Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HB Global Ltd
KLSE:5187
|
Malaysia | RM71.97 Million |
|
CGN Resources Ltd
AU:CGR
|
Australia | AU$70.82K |
|
Instituto Rosenbusch S.A.
BA:ROSE
|
Argentina | AR$8.27 Billion |
|
Hydrocarbon Dynamics Ltd
AU:HCD
|
Australia | AU$436.69K |
|
Bayan Mining and Minerals Ltd
AU:BMM
|
Australia | AU$829.46K |
|
Themac Resources Group Limited
V:MAC
|
Canada | CA$192.44 Million |
|
Kontigo Care AB
ST:KONT
|
Sweden | Skr13.13 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down DMD Digital Health Connections Group Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see DMD Digital Health Connections Group Inc asset portfolio.
Liquidity & Leverage Metrics
DMD Digital Health Connections Group Inc Total Liabilities Ratios Explained
DMD Digital Health Connections Group Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DMD Digital Health Connections Group Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DMD Digital Health Connections Group Inc (2013–2025)
The table below shows the annual total liabilities of DMD Digital Health Connections Group Inc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $37.18 Million | +153.44% |
| 2024-12-31 | $14.67 Million | -7.68% |
| 2023-12-31 | $15.89 Million | +19.60% |
| 2022-12-31 | $13.29 Million | +60.28% |
| 2021-12-31 | $8.29 Million | -38.91% |
| 2017-12-31 | $13.57 Million | -9.33% |
| 2016-12-31 | $14.96 Million | -7.96% |
| 2015-12-31 | $16.26 Million | -16.52% |
| 2014-12-31 | $19.48 Million | +2.59% |
| 2013-12-31 | $18.99 Million | -- |
About DMD Digital Health Connections Group Inc
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloi… Read more